Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous...
Hence then, the article about nls pharmaceutics and kadimastem announce pricing and closing of 1 million equity financing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing )
Also on site :
- Disgraced former Centinela Valley schools Superintendent Jose Fernandez dies
- Outsiders see a circular economy. CoreWeave’s CEO sees a ‘violent change’ rattling the supply chain down to the inside of the earth
- As millions of Gen Zers face unemployment, CEOs of Amazon, Walmart, and McDonald’s say opportunity is still there—if you have the right mindset